MQS Management’s Ionis Pharmaceuticals IONS Stock Holding History

MQS Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,547	Closed	-$247K	–	488
2022 Q4	$247K	Buy	+6,547	New	+$275K	0.17%	267

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

MQS Management's IONS Position: Q1 2023 in Review

MQS Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 6,547 shares — an estimated $247K sold.

MQS Management first reported a position in IONS in Q4 2022 and held it in 1 quarter. The position peaked at $247K in Q4 2022. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

MQS Management reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
MQS Management sold 6,547 Ionis Pharmaceuticals shares in Q1 2023, an estimated $247K.
MQS Management first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
MQS Management's Ionis Pharmaceuticals position peaked at $247K in Q4 2022.
313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on MQS Management's 13F filing for Q1 2023, filed 5 May 2023.